Table 6.
Distribution of antibiotic resistance among uropathogens isolated from the study group
| Antibiotics tested | Isolated organisms (n = 61) | Total (61) | Enterobacteriaceae (n = 33) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| E. coli (n = 30) | K. pneumoniae (n = 2) | E. cloacae (n = 1) | S. aureus (n = 11) | CoNS (n = 17) | Non-ESβLs (n = 27) | ESβLs (n = 6) | p-value | ||
| AUG | 17 (56.67%) | 1 (50%) | 1 | – | – | 19/33 (57.6%) | 15 (55.6%) | 4 (66.7%) | 0.618 |
| FEP | 6 (20%) | 0 | 1 | – | – | 7/33 (21.2%) | 1 (3.7%) | 6 (100%) | < 0.001 |
| CFM | 6 (20%) | 0 | 1 | – | – | 7/33 (21.2%) | 1 (3.7%) | 6 (100%) | < 0.001 |
| CRO | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 0 (0.0%) | 6 (100%) | < 0.001 |
| FOX | 3 (10%) | 0 | 1 | 4 (36.36%) | 8 (47.05%) | 18/61 (26.2%) | 1(3.7%) | 3 (50%) | 0.014 |
| CXM | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 0 (0.0%) | 6 (100%) | < 0.001 |
| AMP | 27 (90%) | 2 (100%) | 1 | – | – | 30/33 (90.9%) | 24 (88.9%) | 6 (100%) | 0.392 |
| NAL | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 2 (7.4%) | 4 (66.7%) | 0.005 |
| CF | 25 (83.33%) | 2 (100%) | 1 | – | – | 28/33 (84.8%) | 22 (81.5%) | 6 (100%) | 0.556 |
| CPD | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 0 (0.0%) | 6 (100%) | < 0.001 |
| CAZ | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 0 (0.0%) | 6 (100%) | < 0.001 |
| NOR | 4 (13.33%) | 0 | 0 | 1 (9.1%) | 8 (47.05%) | 13/61 (21.3%) | 2 (7.4%) | 2 (33.33%) | 0.142 |
| F | 0 | 0 | 0 | 0 | 1 (5.9%) | 1/61 (1.64%) | 0 (0.0%) | 0 (0.0%) | – |
| CIP | 4 (13.33%) | 0 | 0 | 1 (9.1%) | 8 (47.05%) | 13/61 (21.3%) | 2 (7.4%) | 2 (33.33%) | 0.142 |
| CTX | 5 (16.67%) | 0 | 1 | – | – | 6/33 (18.2%) | 0 (0.0%) | 6 (100%) | < 0.001 |
| GEN | – | – | – | 0 | 0 | 0/28 (0.0%) | – | – | – |
| PEN | – | – | – | 10 (90.9%) | 15 (88.2%) | 25/28 (89.3%) | – | – | – |
| TE | – | – | – | 2 (18.18%) | 9 (52.9%) | 11/28 (39.3%) | – | – | – |
| COT | – | – | – | 7 (63.63%) | 14 (82.35%) | 21/28 (75%) | – | – | – |
| AMK | – | – | – | 0 | 0 | 0/28 (0.0%) | – | – | – |
| DOX | – | – | – | 2 (18.18%) | 10 (58.82%) | 12/28 (42.68%) | – | – | – |
| C | – | – | – | 3 (27.27%) | 9 (52.9%) | 12/28 (42.68%) | – | – | – |
| ERY | – | – | – | 2 (18.18%) | 9 (52.9%) | 11/28 (39.3%) | – | – | – |
Italic values means the observed difference is statistically significant (p < 0.05)
“–“ Not done; AUG, amox-clavulanic acid; FEP, cefepime; CFM, cefixime; CRO, ceftriaxone; FOX, cefoxitin; CXM, cefuroxime; AMP, ampicillin; NAL, nalidixic acid; CF, cephalothin; CPD, cefpodoxime; CAZ, ceftazidime; NOR, norfloxacin; F, nitrofurantoin; CIP, ciprofloxacin; CTX, cefotaxime; PEN, penicillin; TE, tetracycline; COT, cotrimoxazole; AMK, amikacin; DOX, doxycycline; C, chloramphenicol, and ERY, erythromycin